John Robert Mackey
Impact in
- Oncology top 0.05%
- Cancer survivorship and care
- Cancer Treatment and Pharmacology
- HER2/EGFR in Cancer Research
- Bone health and treatments
- Lymphatic System and Diseases
- Physiology top 0.1%
- Nutrition and Health in Aging
Papers in
- Oncology 133
- Cancer survivorship and care 41
- Cancer Treatment and Pharmacology 28
- HER2/EGFR in Cancer Research 21
- Pancreatic and Hepatic Oncology Research 12
-
- Breast Cancer Treatment Studies 21
- Co-authors
- Kerry S. Courneya (57 shared papers)Lee W. Jones (27 shared papers)Carol E. Cass (44 shared papers)Charles Dumontet (20 shared papers)M. Haykowsky (23 shared papers)Adrian Fairey (8 shared papers)Karen A. Gelmon (29 shared papers)Evangelos D. Michelakis (3 shared papers)
- Journals
- Journal of Clinical Oncology (25 papers)Cancer (12 papers)Clinical Cancer Research (11 papers)Scientific Reports (10 papers)The Oncologist (9 papers)
- Partner nations
- CanadaUnited StatesFrance
In The Last Decade
John Robert Mackey
307 papers receiving 25.2k citations
John Robert Mackey's Hit Papers
Peers
Comparison fields: 5 of 180
- Oncology 12.5k
- Physiology 1.2k
- Cancer Research 3.4k
- Pulmonary and Respiratory Medicine 3.2k
- Cardiology and Cardiovascular Medicine 2.1k
Countries citing papers authored by John Robert Mackey
This map shows the geographic impact of John Robert Mackey's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by John Robert Mackey with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites John Robert Mackey more than expected).
Fields of papers citing papers by John Robert Mackey
This network shows the impact of papers produced by John Robert Mackey. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by John Robert Mackey. The network helps show where John Robert Mackey may publish in the future.
Co-authors
The 25 scholars most cited alongside John Robert Mackey, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 315 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Effects of Aerobic and Resistance Exercise in Breast Cancer Patients Receiving Adjuvant Chemotherapy: A Multicenter Randomized Controlled Trial Hit paper breakdown → | 2007 | 924 |
| 2 | Sarcopenia as a Determinant of Chemotherapy Toxicity and Time to Tumor Progression in Metastatic Breast Cancer Patients Receiving Capecitabine Treatment Hit paper breakdown → | 2009 | 892 |
| 3 | Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial. Hit paper breakdown → | 2002 | 737 |
| 4 | Long‐term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma Hit paper breakdown → | 2003 | 695 |
| 5 | Trastuzumab Plus Anastrozole Versus Anastrozole Alone for the Treatment of Postmenopausal Women With Human Epidermal Growth Factor Receptor 2–Positive, Hormone Receptor–Positive Metastatic Breast Cancer: Results From the Randomized Phase III TAnDEM Study Hit paper breakdown → | 2009 | 641 |
| 6 | Metabolic Modulation of Glioblastoma with Dichloroacetate Hit paper breakdown → | 2010 | 621 |
| 7 | Randomized Controlled Trial of Exercise Training in Postmenopausal Breast Cancer Survivors: Cardiopulmonary and Quality of Life Outcomes Hit paper breakdown → | 2003 | 619 |
| 8 | 2008 | 575 | |
| 9 | Gastric Adenocarcinoma Hit paper breakdown → | 2005 | 569 |
| 10 | Functional nucleoside transporters are required for gemcitabine influx and manifestation of toxicity in cancer cell lines. | 1998 | 515 |
| 11 | 2002 | 507 | |
| 12 | 2009 | 421 | |
| 13 | 2008 | 362 | |
| 14 | Cardiopulmonary Function and Age-Related Decline Across the Breast Cancer Survivorship Continuum Hit paper breakdown → | 2012 | 354 |
| 15 | 2007 | 353 | |
| 16 | 2004 | 345 | |
| 17 | 2009 | 332 | |
| 18 | 2008 | 316 | |
| 19 | 1999 | 302 | |
| 20 | 2004 | 293 |
About John Robert Mackey
John Robert Mackey is a scholar working on Oncology, Cancer Research, Physiology, Cardiology and Cardiovascular Medicine and Molecular Biology, having authored 315 papers that have together received 26.2k indexed citations. Recurring topics across this work include Cancer survivorship and care (41 papers), Chemotherapy-induced cardiotoxicity and mitigation (29 papers), Cancer Treatment and Pharmacology (28 papers), Adenosine and Purinergic Signaling (25 papers), HER2/EGFR in Cancer Research (21 papers), Breast Cancer Treatment Studies (21 papers), Childhood Cancer Survivors' Quality of Life (13 papers) and Pancreatic and Hepatic Oncology Research (12 papers). The work is most often cited by research in Oncology (12.5k citations), Physiology (1.2k citations), Cancer Research (3.4k citations), Pulmonary and Respiratory Medicine (3.2k citations) and Cardiology and Cardiovascular Medicine (2.1k citations). John Robert Mackey has collaborated with scholars based in Canada, United States and France. Frequent co-authors include Kerry S. Courneya, Lee W. Jones, Carol E. Cass, Charles Dumontet, M. Haykowsky, Adrian Fairey, Karen A. Gelmon, Evangelos D. Michelakis, Christine M. Friedenreich and Donald C. McKenzie. Their work appears in journals such as Journal of Clinical Oncology, Cancer, Clinical Cancer Research, Scientific Reports and The Oncologist.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.